Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732056 · ClinicalTrials.gov registry record · Phase 1
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
A Phase 1 study, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00732056 is a Phase 1 study that has completed, run by Geron Corporation. The registered enrollment target is 24 participants.
The verdict
NCT00732056, a Phase 1 study, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of GRN163L in combination with paclitaxel and bevacizumab in patients with locally recurrent or metastatic breast cancer (MBC)
Interventions
- DRUG GRN163L
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732056
The ClinicalTrials.gov registry entry for NCT00732056 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GRN163L is the first listed.
NCT00732056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00732056 about?
NCT00732056 is a clinical study titled "A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer". The purpose of this study is to determine the maximum tolerated dose (MTD) of GRN163L in combination with paclitaxel and bevacizumab in patients with locally recurrent or metastatic breast cancer (MBC)
What is the current status of trial NCT00732056?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-07. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00732056?
The interventions under investigation include: GRN163L (DRUG).
Who is sponsoring clinical trial NCT00732056?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.